Amneal Achieves Second US Biosimilars Approval with ALYMSYS^® (Bevacizumab-Maly)

Amneal Pharmaceuticals, Inc. announced that the US FDA has approved the Company’s Biologics License Application for bevacizumab-maly, a biosimilar referencing Avastin®.